Document:

5th Amendment, dtd June 4, 2007, to Option Agreement

 Exhibit 10.1 
 FIFTH AMENDMENT TO OPTION AGREEMENT 
 THIS FIFTH AMENDMENT (this “Fifth Amendment”) is made as of
June 4, 2007, by and between SAHARA LAS VEGAS CORP., a Nevada corporation (“Optionor”), and LVTI LLC, a Delaware limited liability company (“Optionee”). 
 RECITALS 
 Whereas, Optionor and Optionee entered into that certain Option Agreement,
dated as of June 24, 2006 (the “Original Agreement”); 
 Whereas Optionor and Optionee entered into that certain First
Amendment to Option Agreement, dated as of September 13, 2006 (the “First Amendment”); 
 Whereas Optionor and Optionee
entered into that certain Second Amendment to Option Agreement, dated as of December 15, 2006 (the “Second Amendment”); 
 Whereas Optionor and Optionee entered into that certain Third Amendment to Option Agreement, dated as of March 27, 2007 (the “Third Amendment”); 
 Whereas Optionor and Optionee entered into that certain Fourth Amendment to Option Agreement, dated as of March 30, 2007 (the “Fourth Amendment”, and collectively with the First Amendment, the Second
Amendment, the Third Amendment, and the Original Agreement, the “Agreement”); and 
 Whereas, Optionor and Optionee now wish to
amend the Agreement as provided below in this Fifth Amendment; 
 WITNESSETH: 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree to
amend the Agreement as follows: 
 1. The first clause of the first sentence of Paragraph 1.2 of the Agreement, which was previously
amended pursuant to the First Amendment, is hereby deleted and the following clause is substituted in lieu thereof: 
 “The term of the
Option shall commence on the date of this Agreement and shall terminate at midnight Las Vegas time on June 30, 2008 (the “Option Term”);” 

 2. Clause (iii) of Paragraph 2.2 of the Agreement, which was previously amended pursuant to the
First Amendment, is hereby deleted and the following new clause (iii) is hereby substituted in lieu thereof: 
 “(iii)(A) On or before October 1, 2007, and thereafter on or before the
first (1st) day of each subsequent calendar month until the earlier of the Closing or March 31, 2008, the
monthly amount of Two Million Three Hundred Twenty-Nine Thousand One Hundred Sixty-Seven and No/100 Dollars ($2,329,167.00) and (B) commencing April 1, 2008, and thereafter on or before the first (1st) day of each subsequent calendar month until the earlier of the Closing or the expiration of the Option Term, the monthly amount of Two Million
Eight Hundred Sixty-Six Thousand Six Hundred Sixty-Seven and No/100 Dollars ($2,866,667.00) (each installment paid pursuant to clause (A) and (B) is hereinafter referred to as a “Carry Option Payment”).” 
 3. The fifth sentence in Paragraph 2.2 following clause (iii) thereof, which was previously amended pursuant to the First Amendment, is hereby
amended by adding the following words to the end of the sentence after the words “in accordance with Paragraph 2.1 of this Agreement”: 
 “; provided, however, that if the Closing Date occurs on any day other than the last day of a calendar month and Optionee has paid a Carry Option Payment for such month, then the pro rata portion of such Carry Option Payment (prorated
based on the number of days in such month in which the Closing Date occurs) applicable to the remaining number of days following the Closing Date in such month shall be a credit to Optionee against the Purchase Price (such credit a “COP
Credit”).” 
 4. Paragraphs 9.1.1(c) and 9.1.2(b) of the Agreement, which were previously amended pursuant to the First
Amendment, are hereby amended by adding the following words to the end of the parenthetical (and within such parenthetical) found in each Paragraph that reads “(with credit for the Initial Deposit, the Second Deposit and any Extension Payment
Credit Amount (if any), but not for any Carry Option Payments)”: “, except for the amount of any COP Credit, which shall be a credit to Optionee against the Purchase Price in accordance with Paragraph 2.2 of this Agreement”.

 5. This Fifth Amendment may be signed in any number of counterparts, which shall be considered collectively as a single document.
Facsimile signatures will be treated as originals for all purposes. 
 6. Except as amended hereby, the Agreement is unchanged and as amended
hereby the Agreement shall remain in full force and effect. 
 [Remainder of Page Intentionally Blank. Signatures on Following Page.]

  

 2 

 IN WITNESS WHEREFORE, the parties hereto have executed this Fifth Amendment as of the date first
hereinabove written. 
  

									
	OPTIONOR:	 		 	OPTIONEE:
			
	 SAHARA LAS VEGAS CORP.,
 a Nevada
corporation
	 		 	 LVTI LLC,
 a Delaware limited liability
company

					
	By:	 	/s/ Paul W. Lowden	 		 	By:	 	/s/ Christopher Milam
	Name:	 	Paul W. Lowden	 		 	Name:	 	Christopher Milam
	Title:	 	President	 		 	Title:	 	Chairman

 GUARANTY 
 The undersigned hereby guarantees the performance of the obligations of Optionor under the Agreement as amended by the foregoing Fifth Amendment. 
  

									
		 		 	GUARANTOR:
			
		 		 	 ARCHON CORPORATION,
 a Nevada
corporation
  

					
		 		 		 	By:	 	/s/ Paul W. Lowden
		 		 		 	Name:	 	Paul W. Lowden
		 		 		 	Title:	 	President

  

 3License Agreement by and between The Scripps Research Institute and Repligen Co.

 Exhibit 10.18 
 WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. 
  
 LICENSE AGREEMENT 
 by and between 
 THE SCRIPPS RESEARCH
INSTITUTE, 
 a California nonprofit 
 public benefit corporation 
 and 
 REPLIGEN CORPORATION, 
 a Delaware corporation 

 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	Page
	1.	  	Definitions	  	4
		  	1.1	  	Affiliate	  	4
		  	1.2	  	Confidential Information	  	4
		  	1.3	  	Field	  	5
		  	1.4	  	Licensed Patent Rights	  	5
		  	1.5	  	Licensed Product	  	5
		  	1.6	  	Licensed Process	  	5
		  	1.7	  	Licensed Service	  	5
		  	1.8	  	Major Market Country	  	5
		  	1.9	  	Net Sales	  	5
		  	1.10	  	Valid Claim	  	6
		  	1.11	  	Novartis Research Products Nonexclusive License	  	6
			
	2.	  	Grant of License	  	6
		  	2.1	  	Grant of License for Licensed Products	  	6
		  	2.2	  	Grant of License for Licensed Processes	  	6
		  	2.3	  	Grant of License for Licensed Services	  	7
		  	2.4	  	Sublicensing	  	7
		  	2.5	  	No Other License	  	7
		  	2.6	  	Governmental Interest	  	7
		  	2.7	  	Reservation of Rights	  	7
		  	2.8	  	Novartis Non-Exclusive License	  	7
			
	3.	  	Royalties	  	8
		  	3.1	  	License Issue Royalty	  	8
		  	3.2	  	Equity	  	8
		  	3.3	  	Minimum Annual Royalty	  	8
		  	3.4	  	Running Royalties for Licensed Products	  	8
		  	3.5	  	Running Royalties for Licensed Processes	  	8
		  	3.6	  	Running Royalties for Licensed Services	  	9
		  	3.7	  	Multiple Royalties	  	9
		  	3.8	  	Arms-Length Transactions	  	9
		  	3.9	  	Duration of Royalty Obligations	  	9
			
	4.	  	Non-royalty Revenues	  	9
		  	4.1	  	Sublicense Revenues	  	9
		  	4.2	  	Product Development Milestones	  	10
		  	4.3	  	Certain Additional Terms	  	10
			
	5.	  	Royalty Payments	  	11
		  	5.1	  	Sales by Licensee	  	11
		  	5.2	  	Sales by Sublicensees	  	11

  

 i 

							
	6.	  	Reports on Progress, Benchmarks, Sales or Payments	  	11
		  	6.1	  	Commercial Development Plan and Benchmarks	  	11
		  	6.2	  	Progress Reports on Commercial Development Plan and Benchmarks	  	11
		  	6.3	  	Reports on Revenues and Payments	  	12
		  	6.4	  	Royalty Payments	  	13
		  	6.5	  	Foreign Sales	  	13
		  	6.6	  	Foreign Taxes	  	13
			
	7.	  	Record Keeping	  	13
			
	8.	  	Patent Matters	  	14
		  	8.1	  	Patent Prosecution and Maintenance	  	14
		  	8.2	  	Information to Licensee	  	14
		  	8.3	  	Patent Costs	  	14
		  	8.4	  	Ownership	  	15
		  	8.5	  	TSRI Right to Pursue Patent	  	15
		  	8.6	  	Infringement Actions.	  	15
			
	9.	  	Indemnity and Insurance	  	16
		  	9.1	  	Indemnity	  	16
		  	9.2	  	Insurance	  	17
			
	10.	  	Limited Warranty	  	17
		  	10.1	  	Limited Warranty	  	18
			
	11.	  	Confidentiality and Publication	  	18
		  	11.1	  	Treatment of Confidential Information	  	18
		  	11.2	  	Publications	  	19
		  	11.3	  	Publicity	  	19
			
	12.	  	Term and Termination	  	19
		  	12.1	  	Term	  	19
		  	12.2	  	Termination Upon Mutual Agreement	  	19
		  	12.3	  	Termination by TSRI	  	19
		  	12.4	  	Termination by Licensee	  	20
		  	12.5	  	Rights Upon Expiration	  	20
		  	12.6	  	Rights Upon Termination	  	20
		  	12.7	  	Work-in-Progress	  	20
		  	12.8	  	Final Royalty Report	  	21
			
	13.	  	Assignment; Successors	  	21
		  	13.1	  	Assignment	  	21
		  	13.2	  	Binding Upon Successors and Assigns	  	21
			
	14.	  	General Provisions	  	21
		  	14.1	  	Independent Contractors	  	21
		  	14.2	  	Late Payments	  	21

  

 ii 

											
		 	14.3	 		 		  	Governmental Approvals and Marketing of Licensed Products	  	21
		 	14.4	 		 		  	Patent Marking	  	21
		 	14.5	 		 		  	No Use of Name	  	21
		 	14.6	 		 		  	U.S. Manufacture	  	22
		 	14.7	 		 		  	Foreign Registration	  	22
		 	14.8	 		 		  	Use of Materials	  	22
		 	14.9	 		 		  	Arbitration	  	22
		 	14.10	 		 		  	Entire Agreement; Modification	  	23
		 	14.11	 		 		  	California Law	  	23
		 	14.12	 		 		  	Headings	  	23
		 	14.13	 		 		  	Severability	  	24
		 	14.14	 		 		  	No Waiver	  	24
		 	14.15	 		 		  	Name	  	24
		 	14.16	 		 		  	Attorneys’ Fees	  	24
		 	14.17	 		 		  	Notices	  	24
		 	14.18	 		 		  	Compliance with U.S. Laws	  	25

  

 iii 

 LICENSE AGREEMENT 
 This License Agreement is entered into and made effective as of this 6th day of April, 2007 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit
public benefit corporation (“TSRI”) located at 10550 North Torrey Pines Road, La Jolla, California 92037, and Repligen Corporation, a Delaware corporation (“Licensee”) located at 41 Seyon Street, Waltham, Massachusetts, 02453
with respect to the facts set forth below. 
 RECITALS 
 A. TSRI is engaged in fundamental scientific biomedical and biochemical research including research relating to Friedrich’s ataxia (FA). 

B. Licensee is engaged in research and development of products to prevent, diagnose and treat diseases and conditions in humans. 
 C. TSRI has disclosed to Licensee certain technology and TSRI has the right to grant a license to the technology, subject to certain rights of the U.S.
Government resulting from the receipt by TSRI of certain funding from the U.S. Government. 
 D. TSRI desires to grant to Licensee, and
Licensee wishes to acquire from TSRI, a sole worldwide right and license to certain patent rights and materials of TSRI, subject to the terms and conditions set forth herein. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and
conditions set forth herein, TSRI and Licensee hereby agree as follows: 
 1. Definitions. Capitalized terms shall have the meaning set forth herein.

 1.1 Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly controls, or is controlled by
Licensee. The term “control” as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; or
(b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. Unless otherwise specified,
the term Licensee includes Affiliates. 
 1.2 Confidential Information. The term “Confidential Information” shall mean any
and all proprietary or confidential information of TSRI or Licensee which may be exchanged between the parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that
the receiving party can establish by competent proof that it: 
 (a) Is publicly disclosed through no fault of any party hereto, either
before or after it becomes known to the receiving party; or 

 (b) Was known to the receiving party prior to the date of this Agreement, which knowledge was acquired
independently and not from another party hereto (or such party’s employees); or 
 (c) Is subsequently disclosed to the receiving party
in good faith by a third party who has a right to make such disclosure; or 
 (d) Has been published by a third party as a matter of right.

 1.2.1 In the event that Confidential Information is required to be disclosed by law or court order, in which event the party required to
make such disclosure shall limit the same to the minimum required to comply with the law or court order, and prior to making such disclosure that party shall notify the other party, not later than ten (10) days before the disclosure in order to
allow that other party to comment and/or to obtain a protective or other order, including extensions of time and the like, with respect to such disclosure. 
 1.3 Field. The term “Field” shall mean the prevention, diagnosis and treatment of conditions or diseases in humans. 
 1.4 Licensed Patent Rights. The term “Licensed Patent Rights” shall mean rights arising out of or resulting from (a) the U.S./PCT Patent Application(s) set forth on Exhibit A; (b) the
foreign patent applications of (a); (c) the patents proceeding from (a) and (b); (d) divisionals, continuations, reissues, reexaminations, and extensions of any patent or application set forth in (a)- (c) above; and (e) all
claims of continuations-in-part that are entitled to the benefit of the priority date of (a). 
 1.5 Licensed Product. The term
“Licensed Product” shall mean any product, the manufacture, use, importation, sale or offer for sale of which in or into a particular country is covered by a Valid Claim within the Licensed Patent Rights. Whether a product is a
“Licensed Product” shall be determined on a country-by-country basis. 
 1.6 Licensed Process. The term “Licensed
Process” shall mean any process, the performance of which is covered by a Valid Claim of Licensed Patent Rights. Whether a process is a “Licensed Process” shall be determined on a country-by-country basis. 
 1.7 Licensed Service. The term “Licensed Service” shall mean the performance of a service by Licensee or a sublicensee for a third
party, which performance uses or incorporates a Licensed Product or Licensed Process. Whether a service is a “Licensed Service” shall be determined on a country-by-country basis. 
 1.8 Major Market Country. The term “Major Market Country” shall mean any of the following countries: the United States of America, the
United Kingdom, France, Germany, Spain, Italy, Japan, Canada, or Australia. 
 1.9 Net Sales. The term “Net Sales” shall
mean the gross amount invoiced by Licensee, or sublicensee, or any of them on all sales of Licensed Products, Licensed Processes and Licensed Services less (a) discounts, chargebacks and rebates actually allowed, whether in cash or trade;
(b) credits for claims, allowances, retroactive price reductions or returned goods; 

 
(c) prepaid freight and insurance; and (d) sales taxes or other governmental charges actually paid in connection with sales of Licensed Products
(but excluding what are commonly known as income taxes and value-added taxes). Net Sales shall include all consideration charged by Licensee or sublicensees in exchange for any Licensed Products, Licensed Processes, or Licensed Services, including
without limitation any monetary payments or any other property whatsoever. For purposes of determining Net Sales, a sale shall be deemed to have occurred when an invoice therefore shall be generated or the Licensed Product shipped for delivery,
Licensed Process, completed, or Licensed Service provided. Sales of Licensed Products by Licensee to any Affiliate or sublicensee which is a reseller thereof shall be excluded, and only the subsequent sale of such Licensed Products by Affiliates or
sublicensees of Licensee to unrelated parties shall be deemed to generate Net Sales hereunder. 
 1.10 Valid Claim. The term
“Valid Claim” shall mean a claim of an issued patent within the Licensed Patent Rights that has not lapsed, expired, been canceled, or become abandoned, and has not been held invalid by a court or other appropriate body of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. The term Valid Claim shall also include the claims of a pending
patent application within the Licensed Patent Rights for a period of six (6) years from the date of first examination (i.e., first office action) of that patent application. 
 1.11 Novartis Research Products Nonexclusive License. “Novartis Research Products Nonexclusive License” shall mean the non-exclusive,
worldwide license rights (without the right to sublicense) granted by Scripps to Novartis under the Licensed Patent Rights to make and use (but not sell) “Research Products”. “Research Products” is defined to mean any product,
process or device which is designed or utilized for discovering, improving or testing a Therapeutic Product, Preventative medicine, or Diagnostic Product. “Diagnostic Product” means any product, process or device that is designed or
utilized for diagnosis of a disease or condition in humans or vertebrate animals. “Preventative medicine” means any product, process or device that is designed or utilized to prevent the occurrence of any disease state in humans or
vertebrate animals. “Therapeutic Product” means any product, process or device which is designed or utilized for treatment or mitigation of an existing disease state in humans or vertebrate animals. 
 2. Grant of License. 
 2.1 Grant of License for
Licensed Products. TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, a sole license under the Licensed Patent Rights to make and have made, to use and have used and to import Licensed Products in the
Field. In addition, TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent Rights to offer to sell, to sell and have sold Licensed Products in the Field.

 2.2 Grant of License for Licensed Processes. TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this
Agreement, a sole license under the Licensed Patent Rights to use and have used Licensed Processes in the Field. In addition, TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive 

 
license under the Licensed Patent Rights to offer to sell, to sell and have sold Licensed Processes in the Field. 
 2.3 Grant of License for Licensed Services. TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, a sole
license under the Licensed Patent Rights to use and have used Licensed Services in the Field. In addition, TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent
Rights to offer to sell, to sell and have sold Licensed Services in the Field. 
 2.4 Sublicensing. Licensee shall have the right to
grant and authorize sublicenses to any party with respect to the rights conferred upon Licensee under this Agreement, provided, however, that any such sublicense shall be subject in all respects to the provisions contained in this Agreement
(excluding the payments specified in Sections 3.1 and 3.2 below). Sublicensees shall not further sublicense without TSRI’s prior written consent, which approval shall not be unreasonably withheld. Licensee shall forward to TSRI a copy of any
and all fully executed agreements within thirty (30) days of execution. 
 2.5 No Other License. This Agreement confers no
license or rights by implication, estoppel, or otherwise under any patent applications or patents of TSRI other than Licensed Patent Rights regardless of whether such patents are dominant or subordinate to Licensed Patent Rights. TSRI and Licensee
hereby agree and acknowledge that nothing in this Agreement, including without limitation the provisions of Sections 2.6, 2.7, and 2.8, create, expressly or implicitly, any obligation for Licensee to grant any rights or licenses, or to provide any
materials or perform any services, to or for TSRI or any Third Party, including without limitation, the United States Government or Novartis. 
 2.6 Governmental Interest. Licensee and TSRI acknowledge that TSRI has received, and expects to continue to receive, funding from the United States Government in support of TSRI’s research activities. Licensee and TSRI
acknowledge and agree that their respective rights and obligations pursuant to this Agreement shall be subject to the rights of the United States Government, which may exist, arise or result from TSRI’s receipt of research support from the
United States Government, including but not limited to, 37 C.F.R. 401, the NIH Grants Policy Statement and the NIH Guidelines for Obtaining and Disseminating Biomedical Research Resources. 
 2.7 Reservation of Rights. TSRI reserves the right to use for any research or educational purposes any Licensed Patent Rights and materials
licensed hereunder, without TSRI being obligated to pay Licensee any royalties or other compensation. In addition, TSRI reserves the right to grant non-exclusive research and educational use licenses to other nonprofit or academic institutions to
Licensed Patent Rights licensed hereunder, without the other nonprofit entity being obligated to pay Licensee any royalties or other compensation. TSRI shall have no obligation to notify or inform Licensee of such use or licenses. 
 2.8 Novartis Non-Exclusive License. The licenses granted under Sections 2.1 and 2.2 of this Agreement are subject to the non-exclusive license
rights granted to Novartis pursuant to the Novartis Research Products Nonexclusive License. 

 3. Royalties 
 3.1 License Issue Royalty. In consideration for TSRI entering into this Agreement, Licensee agrees to pay and shall pay to TSRI a noncreditable, nonrefundable license issue royalty in the amount of Three Hundred Thousand U.S. Dollars
(U.S.$300,000) (“License Issue Royalty”) within fifteen (15) days of the Effective Date. Failure of Licensee to make this payment shall render this Agreement null and void (ab initio). 
 3.2 Equity. In addition to the License Issue Royalty specified in 3.1 above, Licensee shall issue to TSRI Eighty Seven Thousand Four Hundred
Sixty-Four (87,464) shares of Licensee’s common stock, equal to Three Hundred Thousand U.S. Dollars (U.S. $300, 000) within fifteen (15) days of the Effective Date as reported on the Nasdaq Global Market or such other market on which
such shares are then traded. Each share of Licensee common stock shall be valued at the closing price of such shares on the trading day immediately prior to the Effective Date. If the value of the shares is not equal to Three Hundred Thousand U.S.
Dollars (U.S. $300,000) on the one-year anniversary of the Effective Date, Licensee shall make a cash payment to TSRI equal to the difference between the actual total value of the shares on such date and Three Hundred Thousand U.S. Dollars (U.S.
$300,000) within thirty (30) days after the one year anniversary of the Effective Date. 
 3.3 Minimum Annual Royalty. Subject to
the credits described in this Section 3.3, within thirty days following each anniversary of the Effective Date, Licensee agrees to pay and shall pay to TSRI a nonrefundable minimum annual royalty in the amount of [**Confidential Treatment
Requested**] for the twelve (12) month period immediately preceding such anniversary date. Each such minimum annual royalty shall be offset (i.e., reduced by) by any amounts paid, as specified in 3.4, 3.5, 3.6, 4.1, and 4.2. hereunder by
Licensee during the twelve (12) month period immediately preceding the relevant anniversary date. 
 3.4 Running Royalties for
Licensed Products. Licensee agrees to pay and shall pay to TSRI a running royalty on a country by country basis in the amount of [**Confidential Treatment Requested**] of Net Sales of Licensed Products. Licensee shall be entitled to a credit
against royalties due hereunder, of [**Confidential Treatment Requested**] of any royalties paid to any third parties by Licensee, its Affiliates or sublicensees which is necessary in order for Licensee or its Affiliates or sublicensees to make,
use, sell, offer for sale, or import any Licensed Product without infringing any patent or other rights of such third party. The application of such credit shall be limited so that it shall not reduce by more than [**Confidential Treatment
Requested**] the royalties paid hereunder for any given period. 
 3.5 Running Royalties for Licensed Processes. Licensee agrees to
pay and shall pay to TSRI a running royalty on a country by country basis in the amount of [**Confidential Treatment Requested**] of Net Sales of products made using a Licensed Process. Licensee shall be entitled to a credit against royalties due
hereunder, of [**Confidential Treatment Requested**] of any royalties paid to any third parties by Licensee, its Affiliates or sublicensees which is necessary in order for Licensee or its Affiliates or sublicensees to make, use, sell, offer for sale
or perform any Licensed Process without infringing any patent or other rights of such third party. The application of such credit shall be limited so that it shall not reduce by more than [**Confidential Treatment Requested**] the royalties paid
hereunder for any given period. 

 3.6 Running Royalties for Licensed Services. Licensee agrees to pay and shall pay to TSRI
[**Confidential Treatment Requested**] of any and all Net Sales for Licensed Services. Licensee shall be entitled to a credit against royalties due hereunder, of [**Confidential Treatment Requested**] of any royalties paid to any third parties by
Licensee, its Affiliates or sublicensees which is necessary in order for Licensee or its Affiliates or sublicensees to make, use, sell, offer for sale or perform any Licensed Service without infringing any patent or other rights of such third party.
The application of such credit shall be limited so that it shall not reduce by more than [**Confidential Treatment Requested**] the royalties paid hereunder for any given period. 
 3.7 Multiple Royalties. No multiple royalties shall be due because any Licensed Product, Licensed Process or Licensed Service is covered by more
than one of the Licensed Patent Rights. In such case, Licensee shall pay the highest of the royalties owed to TSRI pursuant to Sections 3.4-3.6 above. 
 3.8 Arms-Length Transactions. On sales of Licensed Products, Licensed Processes or Licensed Services which are made in other than an arm’s-length transaction, the value of the Net Sales attributed under
this Section 3 to such a transaction shall be that which would have been received in an arm’s-length transaction, based on sales of like quality and quantity products on or about the time of such transaction. “Arm’s-length
transaction” means a sale between unaffiliated parties. 
 3.9 Duration of Royalty Obligations. The royalty obligations of
Licensee as to each Licensed Product, Licensed Process or Licensed Service shall terminate on a country-by-country basis concurrently with the expiration or termination of the last Valid Claim within Licensed Patent Rights that covers such Licensed
Product or Licensed Process or Licensed Service. 
 4. Non-royalty Revenues. 
 4.1 Sublicense Revenues. Any and all revenues, other than royalties, research and development funding (excluding Licensed Services), and equity
investments made by such sublicensees in Licensee’s stock, pursuant to a stock purchase agreement that is separate from the sublicense agreement, to the extent such stock was sold by Licensee for a price that is above the then-current fair
market value (for avoidance of doubt, the amount above fair market value shall be included within Sublicense Revenue as defined herein). Sublicense Revenue shall be reported and paid to TSRI by Licensee within thirty (30) days of receipt by
Licensee as provided herein. Licensee shall pay to TSRI a non-creditable, non-refundable percentage of these Sublicense Revenues according to the following schedule (“Sublicense Payments”): 
  

			
	 Effective Date of Sublicense Agreement
	 	 Percent of Sublicense Revenues
 Payable to
TSRI

		
	 First period of six months after Effective Date
	 	[**Confidential Treatment Requested**]
	 Second period of six months after Effective Date
	 	[**Confidential Treatment Requested**]

			
	 Third period of six months after Effective Date
	 	[**Confidential Treatment Requested**]
	 Fourth period of six months after Effective Date
	 	[**Confidential Treatment Requested**]
	 During the third year after Effective Date
	 	[**Confidential Treatment Requested**]
	 During or after the fourth year after Effective Date
	 	[**Confidential Treatment Requested**]

 Any non-cash consideration received by Licensee from sublicensees shall be valued at its fair market value as of
the date of receipt. 
 4.2 Product Development Milestones. Licensee agrees to pay and shall pay to TSRI the following non-creditable,
non-refundable product development milestones within thirty (30) days of the first achievement of each milestone with a Licensed Product. All such milestones shall be payable a maximum of one time each regardless of how many times each is
achieved in a particular country and regardless of in how many countries each is achieved. 
  

			
	 Milestone Event
	 	Payment
		
	 First Patient Dosed in a Clinical Trial
 in a Major Market Country
	 	[**Confidential Treatment Requested**]
		
	 First Patient Dosed in a Phase III Trial
 (or its equivalent) in a Major Market Country
	 	[**Confidential Treatment Requested**]
		
	 Acceptance of NDA Filing by the FDA
 (or its equivalent) in a Major Market Country
	 	[**Confidential Treatment Requested**]
		
	 FDA Approval of an NDA to treat Friedrich’s Ataxia
	 	[**Confidential Treatment Requested**]
		
	 FDA Approval of an NDA to treat a disease other than
 Friedrich’s Ataxia
	 	[**Confidential Treatment Requested**]
		
	 European Approval in a Major Market Country
	 	[**Confidential Treatment Requested**]

 4.3 Certain Additional Terms. After Licensee executes its first sublicense pursuant to
Section 2.4, all amounts that Licensee thereafter pays to TSRI under Section 4.2 shall be fully credited only against the Sublicense Payments due from Licensee to TSRI under Section 4.1 for product development milestone payments that
Licensee subsequently receives from its sublicensees under sublicense agreements (“Sublicensee Milestone Payments”). The payments 

 
that Licensee makes to TSRI under Section 4.2 shall not be credited or applied against any other Sublicense Payments due from Licensee to TSRI under
Section 4.1. In order to receive such credit, Licensee shall itemize in detail on its accounting of Sublicense Revenues under Section 4.1 the original amount of Sublicense Payments due under Section 4.1 for Sublicensee Milestone
Payments for each sublicense, and the specific amounts paid to TSRI under Section 4.2 after the date of Licensee’s first sublicense that Licensee wants credited against its Sublicense Payments due under Section 4.1 for Sublicensee
Milestone Payments for each sublicense. If any amounts required to be paid to TSRI under Section 4.2 are due before Licensee executes its first sublicense, but are not actually paid by Licensee to TSRI until after Licensee executes its
first sublicense, then those amounts actually paid by Licensee to TSRI under Section 4.2 shall not be entitled to be credited or applied against Sublicense Payments due under Section 4.1 for Sublicensee Milestone Payments for any
sublicense. 
 5. Royalty Payments. 
 5.1
Sales by Licensee. Royalties payable pursuant to Section 3 herein, shall be payable by Licensee quarterly, within sixty (60) days after the end of each calendar quarter, based upon Net Sales during the immediately preceding calendar
quarter. 
 5.2 Sales by Sublicensees. Licensee agrees to pay and shall pay to TSRI, or cause its sublicensees to pay to TSRI all
royalties pursuant to Section 3 herein resulting from the activities of its sublicensees, within ninety (90) days after the end of each calendar quarter. 
 6. Reports on Progress, Benchmarks, Sales or Payments. 
 6.1 Commercial Development Plan and Benchmarks. Prior to
signing this Agreement, Licensee has provided to TSRI the Commercial Development Plan attached hereto as Exhibit B, under which Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of commercial use. This
Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Exhibit C. 
 6.2 Progress Reports on Commercial Development Plan and Benchmarks. Licensee shall provide written annual reports on its product development progress or efforts to commercialize under the Commercial Development
Plan for each of the Fields within thirty (30) days after June 30 of each year. These progress reports shall include, but not be limited to: progress on research and development, status of applications for regulatory approvals,
manufacturing, sublicensing, marketing, importing, and sales during the preceding calendar year, as well as plans for the present calendar year. TSRI also encourages these reports to include information on any of Licensee’s public service
activities that relate to the Licensed Patent Rights. If reported progress differs from that projected in the Commercial Development Plan and Benchmarks, Licensee shall explain the reasons for such differences. In any such annual report, Licensee
may propose amendments to the Commercial Development Plan, acceptance of which by TSRI may not be denied unreasonably. Licensee agrees to provide any additional information reasonably required by TSRI to evaluate Licensee’s performance under
this Agreement. Licensee may amend the Benchmarks at any time upon written consent by TSRI. TSRI shall not unreasonably withhold approval of any request by Licensee to extend the time periods of this 

 
schedule if such request is supported by a reasonable showing by Licensee of diligence in its performance under the Commercial Development Plan and toward
bringing the Licensed Products to the point of commercial use. Licensee shall amend the Commercial Development Plan and Benchmarks at the request of TSRI to address any Licensed Fields not specifically addressed in the plan originally submitted.

 6.2.1 At any time after two (2) years from the Effective Date of this Agreement, if TSRI, in its sole reasonable judgment, believes
progress reports furnished by Licensee do not demonstrate that Licensee: (a) has put the licensed subject matter into commercial use in at least one Major Market Country, directly or through a sublicense, and is keeping the licensed subject
matter reasonably available to the public; or (b) is engaged in research, development, manufacturing, marketing or sublicensing activity reasonably intended to achieving 6.2.1(a), then TSRI may terminate this Agreement, provided that TSRI shall
provide express written notice to Licensee explaining in reasonably specific detail the reasons for such belief, and Licensee shall have not less than sixty (60) days to cure the applicable diligence failure or provide to TSRI evidence in
support of Licensee’s diligence efforts. Licensee shall report to TSRI the dates for achieving Benchmarks specified in Exhibit C and the first commercial sale of a Licensed Product, Licensed Service, and Licensed Process in each country within
thirty (30) days of such occurrences. 
 6.3 Reports on Revenues and Payments. Licensee shall submit to TSRI, no later than sixty
(60) days after then end of each calendar quarter, a royalty report (the “Royalty Report”) setting forth for such quarter at least the following information: 
  

	 	(a)	the number of Licensed Products sold by Licensee, and its sublicensees; 

  

	 	(b)	the total Net Sales for such Licensed Products; 

  

	 	(c)	the total Net Sales for all Licensed Processes used or sold by Licensee and its sublicensees; 

  

	 	(d)	the total Net Sales for all Licensed Services performed; 

  

	 	(e)	deductions applicable to determine the Net Sales pursuant to Section 1.10; 

  

	 	(f)	the total amount of third party royalties paid, if any, and the calculation of the royalty credit under Sections 3.4, 3.5, and 3.6; 

  

	 	(g)	the amount of Sublicense Revenues received by Licensee; and 

  

	 	(h)	the amount of royalty due on all of the above, or if no royalties are due to TSRI for any reporting period, the statement that no royalties are due and a detailed explanation why
they are not due for that quarterly period. 

 Such Royalty Report shall be certified as correct by an officer of Licensee and shall include a
detailed listing of all deductions from royalties. 

 6.4 Royalty Payments. Licensee agrees to pay and shall pay to TSRI with each Royalty Report the
amount of royalty due with respect to such quarter. If multiple technologies are covered by the license granted hereunder, Licensee shall specify which Licensed Patent Rights are utilized for each Licensed Product, Licensed Process, and/or Licensed
Service included in the Royalty Report. All payments due hereunder shall be deemed received when funds are credited to TSRI’s bank account and shall be payable by check or wire transfer in United States Dollars. 
 6.5 Foreign Sales. The remittance of royalties payable on sales outside the United States shall be payable to TSRI in United States Dollar
equivalents at the official rate of exchange of the currency of the country from which the royalties are payable, as quoted in the Wall Street Journal for the last business day of the calendar quarter in which the royalties are payable. If the
transfer of or the conversion into the United States Dollar equivalents of any such remittance in any such instance is not lawful or possible, the payment of such part of the royalties as is necessary shall be made by the deposit thereof, in the
currency of the country where the sale was made on which the royalty was based to the credit and account of TSRI or its nominee in any commercial bank or trust company of TSRI’s choice located in that country, prompt written notice of which
shall be given by Licensee to TSRI. 
 6.6 Foreign Taxes. Any tax required to be withheld by Licensee under the laws of any foreign
country for any royalties or other amount due hereunder or for the accounts of TSRI shall be promptly paid by Licensee for and on behalf of TSRI to the appropriate governmental authority, and Licensee shall furnish TSRI with proof of payment of such
tax together with official or other appropriate evidence issued by the applicable government authority. Any such tax actually paid on TSRI’s behalf shall be deducted from royalty payments due TSRI. 
 7. Record Keeping. Licensee shall keep, and shall require its Affiliates and sublicensees to keep, accurate records (together with supporting documentation) of
Licensed Products, Licensed Processes and Licensed Services made, used or sold under this Agreement, appropriate to determine the amount of royalties, Sublicense Payments, Product Development Milestone Payments and other monies due to TSRI
hereunder. Such records shall be retained for at least five (5) years following the end of the reporting period to which such records relate. They shall be available during normal business hours for examination and copying by an accountant
selected by TSRI, for the purpose of verifying Licensee’s reports and payments hereunder and its compliance with this Agreement. In conducting examinations pursuant to this Section, TSRI’s accountant shall have access to, and may disclose
to TSRI, all records which TSRI reasonably believes to be relevant to the calculation of royalties under Section 3, non-royalty revenues under Section 4 and Licensee’s compliance with this Agreement. 
 Except as set forth above, TSRI’s accountant shall not disclose to TSRI any information other than information relating to the accuracy of reports
and payments made hereunder and to Licensee’s compliance with this Agreement. 
 Such examination by TSRI’s accountant shall be at
TSRI’s expense, provided that, if such examination shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then Licensee shall pay the cost of such examination (including without
limitation TSRI’s attorney’s fees, accountant’s fees, and other costs) as well as any 

 
additional sum that would have been payable to TSRI had the Licensee reported correctly, plus interest on said sum at the rate of one and one-half percent
(1-1/2%) per month, and provided further, that if a second underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period occurs, then the interest payable on such sum shall be calculated and payable at
the rate of two percent (2%) per month. All payments due hereunder shall be made within fifteen (15) days of receipt of a written demand from TSRI. 
 8. Patent Matters. 
 8.1 Patent Prosecution and Maintenance. From and after the date of this Agreement, the
provisions of this Section 8 shall control the prosecution and maintenance of any patent and patent application included within Licensed Patent Rights. Subject to the requirements, limitations, and conditions set forth in this Agreement, TSRI
shall (a) direct and control the preparation, filing and prosecution of the United States and foreign patent applications within Licensed Patent Rights (including without limitation any reissues, reexaminations, appeals to appropriate patent
offices and/or courts, interferences and foreign oppositions); and (b) maintain the patents issuing therefrom. TSRI shall select the patent attorney, subject to Licensee’s written approval, which approval shall not be unreasonably
withheld. Both parties hereto agree that TSRI may, at its sole discretion, utilize TSRI’s Office of Patent Counsel in lieu of or in addition to independent counsel for patent prosecution and maintenance described herein, and the fees and
expenses incurred by TSRI with respect to work done by such Office of Patent Counsel and/or independent counsel shall be paid as set forth below. Licensee shall have full rights of consultation with the patent attorney so selected on all matters
relating to Licensed Patent Rights. TSRI shall use its best efforts to implement all reasonable and timely requests made by Licensee with regard to the preparation, filing, prosecution and/or maintenance of the patent applications and/or patents
within Licensed Patent Rights. 
 8.2 Information to Licensee. TSRI shall keep Licensee timely informed of the progress of all patent
applications, patents and other submissions relating thereto and give Licensee and Licensee’s counsel reasonable opportunity to review and comment on the text of each patent application within Licensed Patent Rights and other submissions
relating thereto before filing, including, but not limited to, the type and scope of the useful claims and the nature of supporting disclosures. TSRI shall provide Licensee with a copy of such patent application as filed, together with notice of its
filing date and serial number, and each such submission. TSRI shall provide Licensee with copies of all patent applications, amendments, related correspondence, and other relevant documentation relating to such prosecution. 
 8.3 Patent Costs. Licensee acknowledges and agrees that the license granted hereunder is in partial consideration for Licensee’s assumption
of patent costs and expenses as described herein. Licensee agrees to reimburse and shall reimburse TSRI Twenty Four Thousand Six Hundred Forty Three Dollars ($24,643.00) for all patent fees and expenses previously paid or incurred in connection with
Licensed Patent Rights which are as of October 31, 2006. Licensee agrees to pay and shall pay all such past fees, costs, and future cost and patent fees associated with the work performed by TSRI’s Office of Patent Counsel and/or
Independent Counsel to prepare, prosecute, and maintain the Licensed Patent Rights within thirty (30) days after Licensee receives an itemized invoice therefor. Failure of Licensee to pay patent costs and expenses as set forth in this
Section 8.3 shall immediately relieve TSRI from its obligation to 

 
incur any further patent costs and expenses. For the avoidance of doubt, should Licensee be in arrears for any patent costs and expenses due to TSRI for
independent counsel, TSRI shall have the right, at its sole discretion, to cease all patent prosecution and allow Licensed Patent Rights to go abandoned. Such action by TSRI shall not constitute a breach of this Agreement. Payment can be made
directly to independent counsel, or to TSRI, as the Parties may agree. Licensee may elect with a minimum of ninety (90) days prior written notice to TSRI, to discontinue payment for the filing, prosecution and/or maintenance of any patent
application and/or patent within Licensed Patent Rights. Licensee shall remain liable for all patent prosecution and maintenance costs incurred prior to the date of notice of election and for a ninety (90) day period following date of such
notice. Any such patent application or patent so elected shall immediately be excluded from the definition of Licensed Patent Rights and from the scope of the licenses granted under this Agreement, and all rights relating thereto shall revert to
TSRI and may be freely licensed by TSRI. 
 8.4 Ownership. The patent applications filed and the patents obtained by TSRI pursuant to
Section 8.1 hereof shall be owned solely by TSRI, assigned solely to TSRI and deemed a part of Licensed Patent Rights. 
 8.5 TSRI
Right to Pursue Patent. If at any time during the term of this Agreement, Licensee’s rights with respect to Licensed Patent Rights are terminated, TSRI shall have the right to take whatever action TSRI deems appropriate to obtain or
maintain the corresponding patent protection. If TSRI pursues patents under this Section 8.5, Licensee agrees to cooperate fully, including by providing, at no charge to TSRI, all appropriate technical data and executing all necessary legal
documents. 
 8.6 Infringement Actions. 
 8.6.1 Licensee and TSRI each shall inform the other promptly in writing of any alleged infringement by a third party of the Licensed Patent Rights covering Licensed Products, Licensed Services, and/or Licensed
Processes which comes to the its attention and of any reasonably available evidence thereof. 
 8.6.2 Prosecution of Infringements.
During the term of this Agreement, the parties shall consult with each other regarding such infringement of any patent within such Licensed Patent Rights. In order to maintain the licenses granted hereunder in force, Licensee shall prosecute any and
all infringements of any Licensed Patent Rights by third parties, unless such infringement is outside of the Field or is economically immaterial. Licensee may enter into settlements, stipulated judgments or other arrangements respecting such
infringement, at its own expense, but only with the prior written consent of TSRI, which consent shall not be unreasonably withheld. TSRI shall permit any action to be brought in its name if required by law, and Licensee shall hold TSRI harmless
from any costs, expenses or liability respecting all such infringements. TSRI agrees to provide reasonable assistance of a technical nature which Licensee may require in any litigation arising in accordance with the provisions of this
Section 8.6.2, for which Licensee shall pay to TSRI a reasonable hourly rate of compensation. In the event Licensee fails to prosecute any such infringement, Licensee shall notify TSRI in writing promptly and TSRI shall have the right, but not
the obligation, to prosecute such infringement on its own behalf. 

 8.6.3 Allocation of Recovery. Any damages or other recovery from an infringement action undertaken
pursuant to Section 8.6.2 shall first be used to reimburse the parties for the costs and expenses incurred in such action, and thereafter: (a) the amount attributable to compensatory damages shall be treated as Net Sales and allocated
pursuant to Section 3; and (b) all non-compensatory damages (whether denoted at punitive or a statutory penalty) shall be divided seventy percent (70%) to Licensee and thirty (30%) to TSRI. If TSRI prosecutes any such action
under Section 8.6.2, then any damages or other recovery net of the parties’ costs and expenses incurred in such infringement shall be the sole property of TSRI. 
 9. Indemnity and Insurance. 
 9.1 Indemnity. Licensee hereby agrees to indemnify, defend (by
counsel reasonably acceptable to TSRI) and hold harmless TSRI and any parent, subsidiary or other affiliated entity and their trustees, directors, officers, employees, scientists, agents, successors, assigns and other representatives (collectively,
the “Indemnitees” from and against all damages, claims, liabilities, losses and other expenses, including without limitation reasonable attorney’s fees, expert witness fees and costs , arising from claims asserted by third parties
(“Claim”), that arise out of or relate to (a) Licensee’s or any sublicensee’s use of any of the Licensed Patent Rights, (b) alleged defects or other problems with any of the Licensed Products, Licensed Processes, or
Licensed Services manufactured, sold, distributed or rendered by Licensee or any sublicensee, including without limitation any personal injuries, death or property damages related thereto, (c) any advertising or other promotion of the Licensed
Products, Licensed Processes, or Licensed Services by Licensee or any sublicensees, (d) any allegations that the Licensed Products, Licensed Processes, or Licensed Services developed, manufactured, sold, distributed or rendered by Licensee or
any sublicensee and/or any trademark, service mark, logo, symbol, slogan or other materials used in connection with or to market a Licensed Product, Licensed Process, or Licensed Service violates or infringes upon the trademarks, service marks,
trade dress, trade names, copyrights, patents, works of authorship, inventorship rights, trade secrets, database rights, rights under unfair competition laws, rights of publicity, privacy or defamation, or any other intellectual or industrial
property rights of any third party, (e) Licensee’s or any sublicensee’s failure to comply with any applicable laws, rules or regulations, (f) Licensee’s or any sublicensee’s transactions with third parties or the
operation of their respective businesses, and/or (g) the negligent or willful acts or omissions of Licensee or any sublicensee; provided that to the extent any Claim arises out of any negligent action, or failure to act, by TSRI or TSRI’s
breach of any law or regulation, or breach of this Agreement by TSRI, Licensee’s liability for damages will be proportioned to the extent of the respective fault of Licensee and TSRI. Licensee shall not enter into any settlement of such Claims
that admits liability on behalf of TSRI without TSRI’s prior written consent. Indemnitees, at their expense, shall have the right to retain separate independent counsel to assist in defending any such Claims. In the event Licensee fails to
promptly indemnify and defend such Claims and/or pay Indemnitees’ expenses as provided above, Indemnitees shall have the right to defend themselves, and in that case, Licensee shall reimburse Indemnitees for all of their reasonable
attorney’s fees, costs and damages incurred in settling or defending such Claims within thirty (30) days of each of Indemnitees’ written requests. This indemnity shall be a direct payment obligation and not merely a reimbursement
obligation of Licensee to Indemnitees. 

 9.2 Insurance. Licensee shall name TSRI and Indemnitees as “additional insureds” on any
commercial general liability and product liability insurance policies maintained by Licensee, its Affiliates and sublicensees applicable to the Licensed Products, Licensed Services, and Licensed Processes. 
 9.2.1 Beginning at the time any such Licensed Product, Licensed Process, Licensed Service, or Licensed Material is being commercially distributed or sold
(other than for the purpose of obtaining regulatory approvals) by Licensee or by a sublicensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per
incident and $2,000,000 annual aggregate and naming the Indemnitees as additional insureds. During clinical trials of any such product, process or service, Licensee shall, at its sole cost and expense, procure and maintain commercial general
liability insurance in such equal or lesser amount as TSRI shall require, naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage; (ii) broad form contractual
liability coverage for Licensee’s indemnification under this Agreement; and (iii) coverage for TSRI’s litigation costs. If Licensee elects to self-insure all or part of the limits described above (including deductibles or retentions
which are in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to TSRI in its sole discretion. The insurance coverage amounts specified herein or the maintenance of such insurance policies shall not in any way limit
Licensee’s indemnity or other liability under this Agreement. 
 9.2.2 In addition, Licensee, on behalf of itself and its insurance
carriers, waives any and all claims and rights of recovery against TSRI and the Indemnitees, including without limitation all rights of subrogation, with respect to either party’s performance under this Agreement or for any loss of or damage to
Licensee or its property or the property of others under its control. Licensee’s commercial general liability insurance policy shall also include a waiver of subrogation consistent with this paragraph in favor of TSRI and the Indemnitees.
Licensee shall be responsible for obtaining such waiver of subrogation from its insurance carrier. Upon TSRI’s request, Licensee shall deliver to TSRI copies of insurance certificates or binders and such waiver of subrogation that complies with
the requirements of this Section 9. 
 9.2.3 Licensee shall provide TSRI with written evidence of such insurance upon request of TSRI.
Licensee shall provide TSRI with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage within such
fifteen (15) day period, TSRI shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 
 9.2.4 Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (a) the
period that any Licensed Product or Licensed Service relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by Licensee or by a sublicensee, Affiliate or agent of Licensee; and (b) a reasonable period
after the period referred to in Section 9.2.4 (a) above which in no event shall be less than fifteen (15) years. 
 10. Limited
Warranty. 

 10.1 Limited Warranty. TSRI hereby represents and warrants that it has full right and power to
enter into this Agreement and that the Licensed Patent Rights have been prosecuted in good faith by TSRI. TSRI MAKES NO OTHER WARRANTIES CONCERNING LICENSED PATENT RIGHTS OR ANY OTHER MATTER WHATSOEVER, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND TSRI DISCLAIMS ALL SUCH EXPRESS OR IMPLIED WARRANTIES. TSRI MAKES NO
WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF LICENSED PATENT RIGHTS, OR THAT ANY LICENSED PRODUCT OR LICENSED SERVICE WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD
PARTIES ARE IN ANY WAY INFRINGING UPON ANY LICENSED PATENT RIGHTS COVERED BY THIS AGREEMENT. FURTHER, TSRI HAS MADE NO INVESTIGATION AND MAKES NO REPRESENTATION THAT THE LICENSED PATENT RIGHTS ARE SUITABLE FOR LICENSEE’S PURPOSES. 

IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION,
DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER. TSRI’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF
ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY LICENSEE TO TSRI UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF
LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER EITHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. 
 11. Confidentiality and Publication. 
 11.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of five (5) years
after this Agreement expires or terminates, a party receiving Confidential Information of the other party will (a) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary information;
(b) not disclose such Confidential Information to any third party without the prior written consent of the other party; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement. TSRI agrees
that Licensee and its sublicensees shall be permitted to disclose information that relates to the subject matter claimed in the Licensed Patent Rights in connection with the exercise of the rights licensed hereunder by TSRI to Licensee as long as
the disclosure of such information is protected under written obligations of confidentiality which are at least as restrictive as those contained in this Agreement. 

 11.2 Publications. Licensee agrees that TSRI shall have a right to publish scientific data or
results generated by TSRI in accordance with its general policies, and that this Agreement shall not restrict, in any fashion, TSRI’s right to publish. 
 11.3 Publicity. Except as otherwise provided herein or required by law, no party shall originate any publication, news release or other public announcement, written or oral, whether in the public press,
stockholders’ reports, or otherwise, relating to this Agreement or to any sublicense hereunder, or to the performance hereunder or under any such sublicense agreements, without the prior written approval of the other party, which approval shall
not be unreasonably withheld. Once material is so approved for publication, either party shall be permitted to re-publish it thereafter without seeking additional consent from the other party. Notwithstanding the foregoing, Licensee may make such
disclosure as it deems reasonable in order to comply with law, including the files and regulations of the U.S. Securities and Exchange Commission and of the Nasdaq Global Market or such other market on which the Licensee is then listed. Scientific
publications published in accordance with Section 11.2 of this Agreement shall not be construed as publicity governed by this Section 11.3. 
 12.
Term and Termination. 
 12.1 Term. Unless terminated sooner in accordance with the terms set forth herein, this Agreement, and
the licenses granted hereunder, shall expire or terminate upon the expiration of the payment obligations of Licensee as provided in Section 3.9 hereof. 
 12.2 Termination Upon Mutual Agreement. This Agreement may be terminated by mutual written consent of both parties. 
 12.3 Termination by TSRI. TSRI may terminate this Agreement as follows: 
 (a) If Licensee does not
make a payment due hereunder and fails to cure such non-payment (including the payment of interest in accordance with Section 14.2) within thirty (30) days after the date of notice in writing of such non-payment by TSRI; 
 (b) If Licensee defaults in its indemnification and insurance obligations under Section 9; 
 (c) As provided in Section 6.2; 
 (d)
If Licensee shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it. Such termination shall be effective immediately upon TSRI giving written notice to Licensee;

 (e) If an examination by TSRI’s accountant pursuant to Section 7 shows an underreporting or underpayment by Licensee in excess
of twenty percent (20%) for any twelve month period, and a subsequent audit shows a similar underreporting of underpayment by Licensee in excess of twenty (20%) or more for any subsequent calendar year; 

 (f) If Licensee is convicted of a felony, and all rights of appeal with respect thereto have been
exhausted, relating to the manufacture, use or sale of Licensed Products, Licensed Services, or Licensed Processes; or 
 (g) Except as
provided in subparagraphs (a)—(f) above, if Licensee defaults in the performance of any obligations under this Agreement and the default has not been remedied within sixty (60) days after the date of notice in writing of such default by
TSRI. 
 12.4 Termination by Licensee. Licensee may terminate this Agreement by giving ninety (90) days advance written notice of
termination to TSRI. 
 12.5 Rights Upon Expiration. Neither party shall have any further rights or obligations upon the expiration of
this Agreement upon its regularly scheduled expiration date other than the obligation of Licensee to make any and all reports and payments for the final quarterly period. Provided, however, that upon such expiration, each party shall be required to
continue to abide by its non-disclosure obligations as described in Section 11.1 which shall survive shall expiration. The right of TSRI to audit pursuant to Section 7, Licensee’s obligation to indemnify TSRI and maintain insurance as
described in Section 9 and Sections 2.6, 2.7, 6.3, 6.4, 6.5, 6.6, 8.3, 8.4, 10, 11.1, 12 and 14 shall also survive the expiration of this Agreement. 
 12.6 Rights Upon Termination. Notwithstanding any other provision of this Agreement, upon any termination of this Agreement prior to the regularly scheduled expiration date of this Agreement, the licenses
granted hereunder shall terminate and revert to TSRI, and all sublicenses granted by Licensee shall also automatically terminate. Except as otherwise provided in Section 12.7 of this Agreement with respect to work-in-progress, upon such
termination, Licensee shall have no further right to develop, manufacture or market any Licensed Product or Licensed Service, or to otherwise use any Licensed Patent Rights. Upon any such termination, Licensee shall promptly return all materials,
samples, documents, information, and other materials that embody or disclose Licensed Patent Rights; provided, however, that Licensee shall not be obligated to provide TSRI with proprietary information that Licensee can show that it independently
developed. Any such termination shall not relieve either party from any obligations accrued to the date of such termination. Upon such termination, each party shall be required to abide by its nondisclosure obligations as described in
Section 11.1 which shall survive such termination. The right of TSRI to audit pursuant to Section 7, Licensee’s obligation to indemnify TSRI and maintain insurance as described in Section 9, and Sections 2.6, 2.7, 6.3, 6.4,
6.5, 6.6, 8.3, 8.4, 10, 11.1, 12 and 14 shall also survive the termination of this Agreement. 
 12.7 Work-in-Progress. Upon any
such early termination of the licenses granted hereunder in accordance with this Agreement, Licensee shall be entitled to finish any work-in-progress and to sell any completed inventory of a Licensed Product covered by such licenses which remain on
hand as of the date of the termination, so long as Licensee sells such inventory in the normal course of business and at regular selling prices and pays to TSRI the royalties applicable to said subsequent sales in accordance with the terms and
conditions as set forth in this Agreement, provided that no such sales shall be permitted after the expiration of six (6) months after the date of termination. 

 12.8 Final Royalty Report. Upon termination or expiration of this Agreement, Licensee shall submit
a final report to TSRI, and any payments due TSRI and unreimbursed patent expenses invoiced by TSRI shall become immediately payable. 
 13. Assignment;
Successors. 
 13.1 Assignment. This Agreement may not be assigned or otherwise transferred (whether voluntarily, by operation of
law or otherwise) by Licensee without the prior written consent of TSRI which shall not be unreasonably withheld; provided however that Licensee may, without such consent, assign this Agreement and its rights and obligations hereunder to an
Affiliate or in connection with the transfer or sale of all of its business, or in the event of its merger, consolidation, change in control, or other similar transaction. Any and all other assignments of this Agreement or any rights granted
hereunder by Licensee without the prior written consent of TSRI are void. 
 13.2 Binding Upon Successors and Assigns. Subject to the
limitations on assignment herein, this Agreement shall be binding upon and inure to the benefit of any successors in interest and assigns of TSRI and Licensee. Any such successor or assignee of Licensee’s interest shall expressly assume in
writing the performance of all the terms and conditions of this Agreement to be performed by Licensee and such written assumption shall be delivered to TSRI as a condition to TSRI’s agreement to consent to any such assignment. 
 14. General Provisions. 
 14.1 Independent
Contractors. The relationship between TSRI and Licensee is that of independent contractors. TSRI and Licensee are not joint venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other
than independent contracting parties. TSRI and Licensee shall have no power to bind or obligate each other in any manner, other than as is expressly set forth in this Agreement. 
 14.2 Late Payments. Except as otherwise provided in Section 7, late payments of any and all payments due hereunder shall be subject to a
charge of one and one-half percent (1-1/2%) per month, or two hundred and fifty dollars ($250) whichever is greater. 
 14.3
Governmental Approvals and Marketing of Licensed Products. Licensee shall be responsible for obtaining all necessary governmental approvals for the development, production, distribution, performance, sale and use of any Licensed Product,
Licensed Service and/or Licensed Process, at Licensee’s expense, including, without limitation, any safety studies. Licensee shall have sole responsibility for any warning labels, packaging and instructions as to the use of Licensed Products
and for the quality control for any Licensed Products. 
 14.4 Patent Marking. To the extent required by applicable law, Licensee
shall mark all Licensed Products or their containers in accordance with the applicable patent marking laws. 
 14.5 No Use of Name.
The use of the name “The Scripps Research Institute”, “Scripps”, “TSRI” or any variation thereof in connection with the advertising, sale or performance of Licensed Products, Licensed Services, or Licensed Processes is
expressly prohibited. 

 14.6 U.S. Manufacture. To the extent required, Licensee agrees to abide by the Preference for
United States Industry as set forth in 37 CFR 401.14 (I). 
 14.7 Foreign Registration. Licensee agrees to register this Agreement
with any foreign governmental agency that requires such registration, and Licensee shall pay all costs and legal fees in connection therewith. In addition, Licensee shall ensure that all foreign laws affecting this Agreement or the sale of Licensed
Products, Licensed Services or Licensed Processes are fully satisfied. 
 14.8 Use of Materials. Licensee agrees that its use of any
materials supplied by TSRI shall comply with all applicable statutes, regulations, and guidelines. Licensee agrees not to use any materials supplied by TSRI for research involving human subjects or clinical trials in the United States without
complying with 21 CFR 50 and 45 CFR 46. Licensee agrees not to use any materials supplied by TSRI for research involving human subjects or clinical trials outside of the United States without complying with the applicable regulations of the
appropriate national control authorities. 
 14.9 Arbitration. Any controversy or claim arising out of or relating to this Agreement,
or the breach thereof, shall be settled by binding confidential arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”), and the procedures set forth below. In the event of any
inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court having jurisdiction thereof. 
 14.9.1 Location. The location of the arbitration shall be in the County of San Diego, California. 
 14.9.2 Selection of Arbitrators. The arbitration shall be conducted by a panel of three neutral arbitrators who are independent and disinterested
with respect to the parties, this Agreement, and the outcome of the arbitration. Each party shall appoint one neutral arbitrator, and these two arbitrators so selected by the parties shall then select the third arbitrator, and all arbitrators must
have substantial experience in mediating or arbitrating cases regarding the same or substantially similar subject matter as the dispute between Licensee and TSRI. If one party has given written notice to the other party as to the identity of the
arbitrator appointed by the party, and the party thereafter makes a written demand on the other party to appoint its designated arbitrator within the next thirty (30) days, and the other party fails to appoint its designated arbitrator within
thirty (30) days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators. 
 14.9.3 Discovery. The arbitrators shall decide any disputes and shall control the process concerning these pre-hearing discovery matters. Pursuant to the Rules of AAA, the parties may subpoena witnesses and
documents for pre-hearing discovery and/or for presentation at the hearing. 
 14.9.4 Case Management. Prompt resolution of any
dispute is important to both parties; and the parties agree that the arbitration of any dispute shall be conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative and control over 

 
the arbitration process (including scheduling of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the
arbitration as expeditiously as is reasonably practical for obtaining a just resolution of the dispute. 
 14.9.5 Remedies. The
arbitrators may grant any legal or equitable remedy or relief that the arbitrators deem just and equitable, to the same extent that remedies or relief could be granted by a state or federal court, provided however, that no punitive damages may be
awarded. No court action shall be maintained seeking punitive damages. The decision of any two of the three arbitrators appointed shall be binding upon the parties. Notwithstanding anything to the contrary in this Agreement, prior to or while an
arbitration proceeding is pending, either party has the right to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce the parties’ rights hereunder. 
 14.9.6 Expenses. The expenses of the arbitration, including the arbitrators’ fees, expert witness fees, and attorney’s fees, may be
awarded to the prevailing party, in the discretion of the arbitrators, or may be apportioned between the parties in any manner deemed appropriate by the arbitrators. Unless and until the arbitrators decide that one party is to pay for all (or a
share) of such expenses, both parties shall share equally in the payment of the arbitrators’ fees as and when billed by the arbitrators. 
 14.9.7 Confidentiality. Except as set forth below and as necessary to obtain or enforce a judgment upon any arbitration award, the parties shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the
decision of the arbitrators. Notwithstanding the foregoing, the parties may disclose information about the arbitration to persons who have a need to know, such as directors, trustees, management employees, witnesses, experts, investors, attorneys,
lenders, insurers, and others who may be directly affected. Additionally, if a party has stock which is publicly traded, the party may make such disclosures as are required by applicable securities laws, but will use commercially reasonable efforts
to seek confidential treatment for such disclosure. 
 14.10 Entire Agreement; Modification. This Agreement and all of the attached
Exhibits set forth the entire agreement and understanding between the parties as to the subject matter hereof, and supersedes all prior or contemporaneous agreements or understandings, whether oral or written. There shall be no amendments or
modifications to this Agreement, except by a written document that is signed by both parties. 
 14.11 California Law. This Agreement
shall be construed and enforced in accordance with the laws of the State of California without regard to the conflicts of laws principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction and venue of the Federal and State
courts located in San Diego County, California, for any action or proceeding to enforce an arbitration award or as otherwise provided in Section 14.9.5, and waives any right to contest or otherwise object to such jurisdiction or venue.

 14.12 Headings. The headings for each article and section in this Agreement have been inserted for convenience of reference only
and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

 14.13 Severability. Should any one or more of the provisions of this Agreement be held invalid or
unenforceable by a court of competent jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions thereof. The parties shall make a good faith effort to replace any invalid or
unenforceable provision with a valid and enforceable one such that the objectives contemplated by them when entering this Agreement may be realized. 
 14.14 No Waiver. Any delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such party’s rights to the
future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 
 14.15 Name. Whenever there has been an assignment or a sublicense by Licensee as permitted by this Agreement, the term “Licensee” as
used in this Agreement shall also include and refer to, if appropriate, such assignee or sublicensee. 
 14.16 Attorneys’ Fees.
In the event of a dispute between the parties hereto or in the event of any default hereunder, the party prevailing in the resolution of any such dispute or default shall be entitled to recover its reasonable attorneys’ fees and other costs
incurred in connection with resolving such dispute or default. 
 14.17 Notices. Any notices required by this Agreement shall be in
writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier, postage prepaid and shall be forwarded to the
respective addresses set forth below unless subsequently changed by written notice to the other party: 
  

			
	For TSRI:	 	The Scripps Research Institute
		 	10550 North Torrey Pines Road, TPC-9
		 	La Jolla, California 92037
		 	Attention: Director, Technology Development
		 	Fax No.: (858) 784-9910
		
	with a copy to:	 	The Scripps Research Institute
		 	10550 North Torrey Pines Road, TPC-8
		 	La Jolla, California 92037
		 	Attention: General Counsel
		 	Fax No.: (858) 784-9399
		
	For Licensee:	 	Repligen Corporation
		 	41 Seyon Street, Building #1
		 	Waltham, MA 02453
		 	Attention: Chief Executive Officer
		 	Fax No.: (781) 250-0115
		
	with a copy to:	 	Goodwin Procter LLP
		 	53 State Street

			
		 	Boston, MA 02109
		 	Attention: Robert E. Puopolo
		 	Fax No.: (617) 523-1231

 Notices shall be deemed delivered upon the earlier of (a) when received; (b) three (3) days after
deposit into the U.S. Mail; (c) the date notice is sent via telefax, telex or cable; or (d) the day immediately following delivery to overnight courier (except Sunday and holidays). 
 14.18 Compliance with U.S. Laws. Nothing contained in this Agreement shall require or permit TSRI or Licensee to do any act inconsistent with the
requirements of any United States law, regulation or executive order as the same may be in effect from time to time. 
 IN WITNESS WHEREOF,
the parties have executed this Agreement by their duly authorized representatives as of the date set forth above. 
  

									
	 TSRI:
	 		 	 LICENSEE:

			
	 THE SCRIPPS RESEARCH INSTITUTE
	 		 	 REPLIGEN CORPORATION

					
	By:	 	 signature illegible
	 		 	 By:
	 	 /s/Walter C. Herlihy

	 Title:
	 	 Senior Vice President Business and Scientific Services
	 		 	 Title:
	 	 President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]